title: Effects of different doses of letrozole on the incidence of early-onset ovarian hyperstimulation syndrome after oocyte retrieval.
abstract: We explored the effects of different doses of letrozole on the incidence of ovarian hyperstimulation syndrome (OHSS) after oocyte retrieval during in vitro fertilization (IVF) in patients with high-risk OHSS. A total of 88 patients were randomly divided into a control group, and groups treated with 2.5 mg, 5 mg, or 7.5 mg of letrozole. We found that from the fifth day after human chorionic gonadotrophin (hCG) treatment, the E2 level decreased and there were statistical differences between the four groups (p < 0.05). From the eighth day after hCG treatment, the luteinizing hormone (LH) level increased, but the progesterone (P) level decreased. There were statistical differences between groups (p < 0.05). From the fifth day after hCG treatment, the level of vascular endothelial growth factor (VEGF) increased in the control, but decreased in the letrozole groups in a dose-dependent manner. There were statistically significant differences between groups (p < 0.001). The incidence of moderate and severe OHSS was lower in the 7.5 mg group than in the control group (p < 0.05). In the patients with high-risk OHSS undergoing whole embryo frozen transfer, treatment with 7.5 mg letrozole may be useful to limit OHSS.
authors.affiliation: Reproductive Medical Center, Henan Provincial People's Hospital, Zhengzhou, China and Reproductive Medical Center, the Affiliated People's Hospital of Zhengzhou University , Zhengzhou , China and.
authors.forename: Qiaohua
authors.initials: Q
authors.lastname: He
authors.forename: Linlin
authors.initials: L
authors.lastname: Liang
authors.forename: Cuilian
authors.initials: C
authors.lastname: Zhang
authors.forename: Hangsheng
authors.initials: H
authors.lastname: Li
authors.forename: Zhaojia
authors.initials: Z
authors.lastname: Ge
authors.forename: Lu
authors.initials: L
authors.lastname: Wang
authors.forename: Shihong
authors.initials: S
authors.lastname: Cui
mesh_terms: D000328:Adult; D047072:Aromatase Inhibitors / Q000008:administration & dosage*; D015415:Biomarkers / Q000097:blood; D002681:China / Q000453:epidemiology; D004305:Dose-Response Relationship, Drug; D004624:Embryo Transfer; D004958:Estradiol / Q000097:blood; D005260:Female; D005307:Fertilization in Vitro; D006801:Humans; D015994:Incidence; D000077289:Letrozole; D007986:Luteinizing Hormone / Q000097:blood; D009570:Nitriles / Q000008:administration & dosage*; D054315:Oocyte Retrieval; D016471:Ovarian Hyperstimulation Syndrome / Q000097:blood / Q000175:diagnosis / Q000453:epidemiology / Q000517:prevention & control*; D010062:Ovulation Induction / Q000009:adverse effects*; D011374:Progesterone / Q000097:blood; D012720:Severity of Illness Index; D013997:Time Factors; D016896:Treatment Outcome; D014230:Triazoles / Q000008:administration & dosage*; D042461:Vascular Endothelial Growth Factor A / Q000097:blood
chemical_list: D047072:Aromatase Inhibitors; D015415:Biomarkers; D009570:Nitriles; D014230:Triazoles; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D011374:Progesterone; D004958:Estradiol; D000077289:Letrozole; D007986:Luteinizing Hormone
keywords: In vitro fertilization; luteal phase; ovarian hyperstimulation syndrome